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Re: First-trimester screening for pre-eclampsia:
moving from personalized risk prediction to
prevention
The recent Editorial by Dr Baschat1 highlighted semi-
nal concepts regarding the controversies surrounding the
prediction of pre-eclampsia2. Thanks to the adjusted pro-
portional distribution of individual variables contributing
to pre-eclampsia risk, calculated from eight studies that
adopted multivariate prediction models, we are informed
that body mass index (BMI) and uterine artery Doppler
velocimetry rank uppermost among the risk factors for
pre-eclampsia.
This might be interpreted either as a controversial find-
ing or, conversely, as strong evidence that these risk
factors are associated with different clinical phenotypes
of pre-eclampsia. The ‘early placental’ risk factors, epit-
omized by abnormal uterine artery Doppler velocimetry,
yield a clinical phenotype of pre-eclampsia that is charac-
terized by a well-known shallow trophoblastic invasion,
small placenta and growth-restricted fetus. The maternal
risk factors, epitomized by increased BMI and the cluster
of risk factors that also happen to constitute metabolic
syndrome, yield a clinical phenotype of pre-eclampsia
that is more frequently associated with normal-weight or
large fetuses and placental damage characterized typically
by ‘terminal villi . . . overcrowded with diminished
intervillous pore size impeding intervillous perfusion with
increasing intervillous hypoxia and syncytiotrophoblast
stress. This type of syncytiotrophoblast stress has no
antecedent pathology, so fetuses are well-grown . . . ’3. We
should interpret the placental origin of pre-eclampsia with
these two distinctions in mind.
The impact of obesity as a maternal risk factor is
exemplified by another paper of Baschat and co-workers4:
algorithms for pre-eclampsia derived from populations
with an average prevalence of maternal BMI > 30 of
less than 20% (such as in many European countries),
achieve at their best a sensitivity that is half that when
applied to a population in which more than 45% of the
female population is obese. It is logical that the two con-
ditions (increasing trend for obesity and early abnormal
trophoblastic invasion) might encroach on one another
and lead to different clinical expressions, since obesity
might interfere with the immune system, and severe dys-
lipidemia might enhance oxidative stress and endothelial
dysfunction5, and worsen decidual atherosis near term6.
This changing scenario of human health further
increases the challenge of prediction and prevention of
pre-eclampsia, yet it should be borne in mind that the
influence of a small placenta from shallow trophoblastic
invasion does not suddenly ‘end’ at 33 + 6 weeks’ gesta-
tion, while the metabolic impact of obesity on endothelial
and placental dysfunction does not suddenly start at
34 + 0 weeks of gestation. Classification of pre-eclampsia
based on time domains should be replaced by classifica-
tion based on pathophysiology, which can be evaluated
objectively using bedside diagnostics such as uterine
artery Doppler velocimetry, fetal ultrasound biometry
and early changes in placental vascular growth factors.
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